ID   MBA72R
AC   CVCL_A2FZ
DR   cancercelllines; CVCL_A2FZ
DR   Wikidata; Q105510040
RX   DOI=10.1186/1479-5876-12-S1-P7;
RX   PubMed=25623468;
CC   Selected for resistance to: ChEBI; CHEBI_91367; Barasertib-HQPA (AZD1152-HQPA).
CC   Sequence variation: Mutation; HGNC; HGNC:1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:6929; MC1R; Simple; p.Val92Met (c.274G>A); ClinVar=VCV000014308; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:6929; MC1R; Simple; p.Asp294His (c.880G>C); ClinVar=VCV000014307; Zygosity=Heterozygous (from parent cell line).
CC   Miscellaneous: Age/sex of donor and metastatic site from personal communication of Guida, Gabriella.
CC   Derived from site: Metastatic; Right temple; UBERON=UBERON_8480027.
DI   NCIt; C3224; Melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_A2FY ! MBA72
SX   Male
AG   82Y
CA   Cancer cell line
DT   Created: 12-01-21; Last updated: 19-12-24; Version: 7
//
RX   DOI=10.1186/1479-5876-12-S1-P7;
RA   Azzariti A., Porcelli L., Quatrale A.E., Sidella L., Iacobazzi R.M.,
RA   Guida G., Maida I., Cocco T., Ferretta A., Strippoli S., Guida S.,
RA   Tommasi S., Paradiso A., Guida M.;
RT   "Barasertib: a novel approach for the treatment of metastatic melanoma.";
RL   J. Transl. Med. 12 Suppl. 1:P7-P7(2014).
//
RX   PubMed=25623468; DOI=10.1186/s12967-015-0385-4; PMCID=PMC4314759;
RA   Porcelli L., Guida G., Quatrale A.E., Cocco T., Sidella L., Maida I.,
RA   Iacobazzi R.M., Ferretta A., Stolfa D.A., Strippoli S., Guida S.,
RA   Tommasi S., Guida M., Azzariti A.;
RT   "Aurora kinase B inhibition reduces the proliferation of metastatic
RT   melanoma cells and enhances the response to chemotherapy.";
RL   J. Transl. Med. 13:26.1-26.13(2015).
//